Literature DB >> 9564664

Comparative effects of GnRH agonist therapy. Review of clinical studies and their implications.

S K Agarwal1.   

Abstract

OBJECTIVE: To understand why differences in gonadotropin releasing hormone (GnRH) agonist therapeutic protocols may affect their efficacy and safety profiles, to understand the important study design facets regarding the literature on GnRH agonist treatment of endometriosis and to compare the efficacy and side effect profiles of FDA-approved GnRH agonist therapies used for the management of endometriosis and consider the implications. STUDY
DESIGN: Review of the English-language literature regarding the use of GnRH agonists for the management of endometriosis.
RESULTS: A limited number of studies are available that directly compare the effects of different GnRH agonists. However, contrary to medical opinion, it appears that there are significant differences between GnRH agonist therapies.
CONCLUSION: The data suggest that it may be possible to reduce doses or alter regimens of GnRH agonists so as to reduce side effects while maintaining efficacy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564664

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Morphological and enzymatic changes caused by a long-term treatment of female rats with a low dose of gonadoliberin agonist and antagonist.

Authors:  Aleksandra Suszka-Świtek; Piotr Czekaj; Jacek Pająk; Rafał Skowronek; Katarzyna Wrona-Bogus; Danuta Plewka; Danuta Kozłowska-Rup; Ryszard Wiaderkiewicz; Andrzej Jankowski
Journal:  Med Sci Monit       Date:  2012-08

2.  Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats.

Authors:  Aleksandra Suszka-Świtek; Florian Ryszka; Barbara Dolińska; Renata Dec; Alojzy Danch; Łukasz Filipczyk; Ryszard Wiaderkiewicz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.